Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other 1Genitourinary 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 8Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Leukemia, Myeloid, Acute 4Hematologic Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Pulmonary Disease, Chronic Obstructive 2Neoplasm Metastasis 2Lymphoma, Follicular 2Leukemia 2Colonic Neoplasms 2COVID-19 2Xerostomia 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Teratoma 1Stroke 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1

Interventions

Standard of Care 2vilanterol 1tocilizumab 1Tiotropium Bromide 1Surgical Procedures, Operative 1Salmeterol Xinafoate 1Rehabilitation 1Practice Guidelines as Topic 1Immunoglobulin G 1Fluticasone-Salmeterol Drug Combination 1Fluticasone 1Educational Status 1Disulfides 1Albuterol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Pulmonary Disease, Chronic Obstructive × Standard of Care × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

NCT00678405 2010-06-25

Trial of a Breathlessness Intervention Service for Intractable Breathlessness

Cambridge University Hospitals NHS Foundation Trust

Phase 3 Unknown
120 enrolled
OtherThoracic

Dyspnea, Heart Failure, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡